Results 201 to 210 of about 42,897 (306)

Prevalence of pain and use of prescription opioids among older adults: results from the Brazilian Longitudinal Study of Aging (ELSI-Brazil). [PDF]

Lancet Reg Health Am, 2023
Mullachery PH, Lima-Costa MF, de Loyola Filho AI.   +2 more
europepmc   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Theory-Based Social Media Intervention for Nonmedical Use of Prescription Opioids in Young Adults: Protocol for a Randomized Controlled Trial. [PDF]

JMIR Res Protoc
Tam CC, Young SD, Harrison S, Li X, Litwin AH.   +4 more
europepmc   +1 more source

Prescription Opioids Dispensed to Patients with Cancer with Bone Metastasis: 2011-2017. [PDF]

Oncologist, 2021
Zhang H, Paice J, Portenoy R, Bruera E, Reid MC, Bao Y.   +5 more
europepmc   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Prescription opioids among older adults: ten years of data across five countries. [PDF]

BMC Geriatr, 2022
Hamina A, Muller AE, Clausen T, Skurtveit S, Hesse M, Tjagvad C, Thylstrup B, Odsbu I, Zoega H, Jónsdóttir HL, Taipale H.   +10 more
europepmc   +1 more source

A call for action: Closing the evidence gap in management of stimulant‐induced psychosis

Addiction, EarlyView.
Abstract Background Stimulant‐induced psychosis (StIP) is emerging as one of most pressing health challenges. Over the past two decades, stimulant‐related harms and psychiatric care demands have risen sharply. Individuals with StIP often present with severe agitation and high suicide risk, and up to half progress to chronic psychotic illness within two
Anne Bouthillier, Heidar Sharafi, Adam Bisaga, Didier Jutras‐Aswad   +3 more
wiley   +1 more source

Pharmaceutical industry use of key opinion leaders to market prescription opioids: A review of internal industry documents. [PDF]

Explor Res Clin Soc Pharm
Gac B, Tavares K, Yakubi H, Khan H, Apollonio DE, Crosbie E.   +5 more
europepmc   +1 more source

Increasing proactive co-dispensing of take-home naloxone with prescription opioids at Ontario community pharmacies. [PDF]

Can Pharm J (Ott), 2022
Qiu Hua Chen A.
europepmc   +1 more source

What anabolic–androgenic steroids reveal about the limits of current harm reduction models

Addiction, EarlyView.
Abstract Background Harm reduction has largely been shaped by responses to psychoactive drug use where the most urgent harms are acute. These models focus on overdose, blood‐borne viruses, and rapid‐onset toxicity related harms. When applied wholesale to anabolic–androgenic steroids (AAS), they obscure the distinctive pharmacology, consumer typologies,
Timothy Piatkowski, Jason M. Nagata, Suzanne Nielsen   +2 more
wiley   +1 more source